Resumen

GALLEGO RUBIO, O.  y  ASOCIACION CATALANA DE INVESTIGACION ONCOLOGICA Y SUS IMPLICACIONES SOCIOSANTIARIAS et al. Phase II assay with pegilated liposomal doxorubicin and cyclophosphamide in patients with advanced ovary cancer resistant to platinum-based drugs. Oncología (Barc.) [online]. 2006, vol.29, n.3, pp.30-39. ISSN 0378-4835.

PURPOSE: To evaluate the efficacy and safeness of patients with advanced ovary cancer resistant to platinum-based drugs receiving a regime of liposomal adriamycin 35 mg/m² and cyclophosphamide 600 mg/m² day 1 every 28 days, up to a maximum of 8 cycles. MATERIAL Y MÉTODOS: Twenty two evaluable patients were enrolled using the indicated phase II methodology. RESULTS: A response was achieved in 5 out of 21 evaluable patients (23.8%; IC: 5.6-42), with 4 PR (19%; IC: 2.3-35.8) and 1 CR (4.8%; IC: 0-13.9). Hematological toxicity was grade 1, 2 anemia in 12 (59%), and 3 (4%), and grade 1-2 neutropenia (26%). Significant non-hematological toxicity was grade 3 fatigue (4%), nausea (4%), and palmoplantar erythrodisesthesia (4%). The mean progression time was 3.03 months (IC: 0.96-5.11). The median of survival was 6.13 months (IC: 4.32-7.95). The mean duration of the response in patients responding to treatment was 4.73 months (IC: 4.59-4.88). CONCLUSION: The pegilated liposomal doxorubicin and cyclophosphamide regime administered to patients with advanced ovary cancer resistant to platinum-based drugs is relatively effective and shows low toxicity.

Palabras clave : Liposomal adriamycin; Cyclophosphamide; Ovary cancer; Platinum-resistant.

        · resumen en Español     · texto en Español     · Español ( pdf )